Recent years have witnessed remarkable progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://katrinaafho411926.ssnblog.com/37738473/exploring-the-future-of-type-2-diabetes-treatment-retatrutide-and-trizepatide